Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Embody vs PauseRX

Embody
Graded #52

Higher grade

vs+8
PauseRX
Graded #147

Lower grade

The verdict

Embody takes it — 76.5/100 to 68.5/100.

Embody grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEmbody +22
88
66
Dose & formulationPauseRX +2
83
85
Clinical oversightEven
83
83
Labs & monitoringEmbody +2
54
52
FulfillmentEmbody +32
93
61
Contract termsPauseRX +16
25
41
Embody · left barPauseRX · right bar

The numbers

MetricEmbodyPauseRX
WeighScore76.5/10068.5/100
GradeCC
Scorecard rank#52#147
Semaglutide$79/mo (all doses, promotional rate, compounded)$199/mo
Tirzepatide$129/mo (all doses, promotional rate, compounded)$249/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Embody

Graded #52 · C

Strengths

  • Among the lowest flat rates in the compounded segment — $79/mo semaglutide and $129/mo tirzepatide injection at every dose
  • Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
  • Available in all 50 states with no insurance friction
  • 24/7 unlimited clinician messaging and dose-adjustment support included
  • Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine

Where it loses points

  • The $79 flat rate relies on an auto-applied promo 'locked forever' — list price in the terms is $199/mo and reviewers allege the lock isn't honored
  • Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
  • Pharmacy partners not publicly named — compounding source transparency is limited
  • Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
PauseRX

Graded #147 · C

Strengths

  • Names its 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) — buyers can independently verify its licensure
  • Names its physician network (Beluga Health) — you can research the clinical platform handling your prescriptions
  • Publishes the FDA compounded-medication disclaimer
  • Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for direct-to-consumer GLP-1 platforms
  • Flat $199 'all doses' compounded semaglutide pricing — no per-tier escalation

Where it loses points

  • States served not listed — site claims nationwide, but you must contact support to confirm availability
  • Restrictive cancellation policy — orders can't be changed or canceled once submitted, and medications can't be returned
  • No named medical director (Beluga Health is the network, not a named MD)
  • LegitScript certification number not shown — badge only, so no direct lookup
  • Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard